A carregar...

Evaluation of the Combination of Metformin and Rapamycin in an MPP+-Treated SH-SY5Y Model of Parkinson’s Disease

Metformin (MET) and rapamycin (RAPA) have been reported to protect against neurodegeneration in cellular and animal models of Parkinson’s disease (PD). MET, which is a first-line drug for type 2 diabetes, and RAPA are known as mTORC1 inhibitors. MET also acts as an AMPK activator, which leads to the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chureerat Norradee, Kawinthra Khwanraj, Tatcha Balit, Permphan Dharmasaroja
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley 2023-01-01
Colecção:Advances in Pharmacological and Pharmaceutical Sciences
Acesso em linha:http://dx.doi.org/10.1155/2023/3830861
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!